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STATE OF THE ART: CONCISE REVIEW
Innovations in the Radiotherapy of Non–Small Cell
Lung Cancer
Steven E. Schild, MD,* and Jeffery A. Bogart, MD†
Background: This review was performed to describe recent inno-
vations in the radiation therapy of lung cancer.
Methods: The literature was reviewed regarding recent research in
the therapy of lung cancer. Emphasis was placed on newer radiation
therapy (RT) techniques.
Results: Advances in physics and computer technology have im-
proved radiation delivery systems. New strategies have been used,
such as altered fractionation patterns, three-dimensional treatment
planning, intensity-modulated RT (IMRT), tomotherapy, stereotac-
tic RT, and heavy ion RT. New technologies will make it possible to
administer higher doses more precisely, which should result in better
disease control, with less toxicity.
Conclusion: Further research will improve the outcome of patients
with lung cancer by providing more effective tools for the RT of this
disease.
Key Words: Lung cancer, Radiation therapy, New technology,
Heavy ion therapy, Intensity-modulated radiation therapy, Stereo-
tactic radiotherapy, Tomotherapy, CyberKnife.
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Lung cancer is the leading cause of cancer deaths, havingcaused an estimated 1.18 million deaths worldwide in
2002.1 In the United States alone, lung cancer resulted in an
estimated 173,770 deaths in 2004.2 Although currently avail-
able therapies cannot cure most patients, there have been
improvements in the outcome over time.3
The standard treatment for locally advanced inoperable
lung cancer used to be radiation therapy (RT) alone. The
Radiation Therapy Oncology Group (RTOG) performed a
phase III trial to evaluate the influence of dose on outcome
and compared 40 Gy in 20 daily fractions, 50 Gy in 25
fractions, and 60 Gy in 30 fractions. The radiographically
determined local failure rates were 48% with 40 Gy, 38%
with 50 Gy, and 27% with 60 Gy. Although the differences in
survival were not significant, this study was used to define the
standard RT dose in the United States as 60 Gy in 30 daily
fractions.4 Conventional RT alone resulted in a median sur-
vival of 10 months and a 5-year survival of 5%.
Phase III trials have demonstrated a survival advantage
for the addition of chemotherapy to RT for non–small-cell
lung cancer (NSCLC). The Cancer and Leukemia Group B
reported that induction chemotherapy (cisplatin plus vinblas-
tine) followed by conventional RT (60 Gy in 30 fractions)
yielded significantly better survival than conventional RT
alone. The median and 5-year survivals were 13.7 months and
17% for the combined therapy versus 9.6 months and 6% for
RT alone (p  0.012).5 Additional phase III trials revealed
that the combination of cisplatin-based chemotherapy plus
RT produced better survival rates than RT alone.6–9
Dose-Fractionation Studies
Randomized prospective studies have failed to demon-
strate an advantage for twice-daily radiotherapy (BIDRT)
compared with once-daily radiotherapy (QDRT) for stage III
NSCLC. The RTOG and North Central Cancer Group (NC-
CTG) studies (RTOG 9410 and NCCTG 94-24-52) compared
chemotherapy plus either BIDRT or QDRT and failed to
show an advantage for BIDRT.10,11 In addition, both RTOG
9410 and a study reported by Furuse et al. revealed signifi-
cantly improved survival with the use of concurrent RT plus
chemotherapy as opposed to sequential therapy.12
Three-times-per-day RT (TIDRT) has shown promise
for NSCLC. Saunders et al. performed a randomized study
that compared QDRT (60 Gy in 30 fractions over 6 weeks)
with continuous hyperfractionated accelerated RT (CHART)
(54 Gy in 36 fractions three times per day over 12 days).13 No
chemotherapy was administered. Patients receiving CHART
had a 2-year survival of 29% versus 20% for those that
received QDRT (p  0.008). These findings demonstrate the
critical importance of treatment time on radiotherapy out-
come. CHART was delivered in only 12 days, whereas the
BIDRT programs used in NCCTG 94-24-52 and RTOG 9410
were approximately 6 weeks long. Accelerated repopulation
of tumor cells during radiotherapy occurred to a lower degree
during CHART, yielding more favorable results.
The Eastern Cooperative Oncology Group initiated a
phase III trial (E-2597) of chemotherapy (two cycles of
paclitaxel plus carboplatin) followed by either QDRT (64 Gy
in 32 fractions over 6.5 weeks) or TIDRT (57.6 Gy in 36
fractions over 12 weekdays) for stage III NSCLC.14 Unfor-
tunately, accrual was slow and the study was closed before
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completion. The median survival was 14.9 months with
QDRT versus 20.3 months with TIDRT.
Mayo Clinic investigators performed a trial with 20
patients treated with escalating doses of daily cisplatin ad-
ministered concurrently with the same regimen of TIDRT
used in the Eastern Cooperative Oncology Group trial. The
median survival was 22 months and 5-year survival was
25%.15 TIDRT appears to be a promising technique for
unresectable NSCLC based on these trials.
Following RT and chemotherapy, the local control rates
based on radiographic studies appear to be substantially better
than those based on pathologic findings. Le Chevalier et al.
performed a trial comparing RT (65 Gy) alone versus RT plus
chemotherapy. Patients underwent serial bronchoscopic biop-
sies and were found to have local control rates at 1 year of
only 15% with RT alone and 17% with combined modality
therapy.16 This finding suggests that local control rates
achieved with RT plus chemotherapy are generally unsatis-
factory. Based on the poor local control rates and dose–
response data, Mehta et al. estimated that it would take a dose
of approximately 85 Gy to achieve a 50% long-term control
rate using standard 2-Gy daily fractions.17 It appears that
higher doses and/or shorter treatment times would be required
to achieve better disease control. Technologies that could be
helpful in accomplishing these goals include the use of
three-dimensional planning, intensity-modulated RT (IMRT),
tomotherapy, stereotactic RT, and charged heavy particle RT.
Three-Dimensional Treatment Planning and
Dose Escalation
Investigators have performed dose-escalation studies
using three-dimensional treatment planning.18–23 Three-di-
mensional planning systems allow one to create beams from
any angle to treat a tumor. Complex treatment plans with
carefully chosen fields can be used to deliver greater than
standard doses while respecting the tolerance of the normal
tissues.24 In addition, there are tools available in three-
dimensional treatment planning systems that can ensure ap-
propriate coverage of the intended target. This was an impor-
tant advance, as targeting errors occurred in up to 31% of
patients on cooperative group trials before the three-dimen-
sional imaging era.25
One major shift in treatment strategy was the irradiation
of gross disease without prophylactic nodal RT. There were
several reasons for this shift in philosophy. The dose of
radiation commonly used (60 Gy in 30 fractions) was not
enough to sterilize bulky epithelial tumors. Simply increasing
the dose delivered to the large volumes of the chest included
when irradiating lymph nodes prophylactically was believed
to cause unacceptable toxicity. In addition, irradiating clini-
cally uninvolved nodal areas prophylactically did not appear
rational when the gross tumor was infrequently controlled.
Many of the patients treated in the earlier dose-escala-
tion trials received no chemotherapy or, in some cases,
sequential therapy. Doses of RT administered have ranged up
to 103 Gy for smaller tumors. Investigators in Michigan,
Rotterdam, and New York reported favorable results with 18-
to 21-month median survival.19,22,23 In addition, isolated
nodal failures in untreated areas were infrequent
(0–6.5%).19,22,23
Rosenzweig et al. summarized the findings of the Me-
morial Sloan-Kettering Cancer Center, University of Michi-
gan, and RTOG trials.25 They divided the tumors by size in
this evaluation of these dose-escalation studies. Small tumors
were peripheral coin lesions for which RT required a V20
(volume of total lung receiving 20 Gy) of less than 25%.
Intermediate tumors were those 4 cm or larger with hilar or
limited mediastinal adenopathy. Large tumors were those
with massive thoracic and mediastinal disease. The maximum
dose administered in various trials ranged from 84 to 102.9
Gy for small tumors, 75.6 to 84 Gy for medium tumors, and
65.1 to 84 Gy for large tumors. The maximum tolerated dose
(MTD) was 83.8 (RTOG 9311) to 84 (Memorial Sloan-
Kettering Cancer Center) Gy for smaller tumors, 77.4 Gy for
intermediate sized tumors (RTOG 9311), and 65.1 Gy for the
larger tumors (University of Michigan).
One important concern is the lack of correlation be-
tween acute and chronic toxicity. Acute toxicity is the end-
point used in most phase I trials, but chronic RT toxicity may
be of greater concern in terms of patient outcome. A recent
update of RTOG 9311 reported late lung toxicity in 15% of
patients with a V20 of less than 25% who received a total
dose of 77.4 Gy or higher and in those with a V20 of between
25% and 37% and who received a total dose of 70.9 Gy or
higher.18 Higher values of V20 have been correlated with
increased risk of pneumonitis.26,27
Recently, Socinski et al. reported a phase I trial that
included induction chemotherapy (carboplatin, irinotecan,
and paclitaxel) followed by concurrent chemotherapy (carbo-
platin and paclitaxel) and RT.28 The RT used in this study
contrasted with the other three-dimensional dose escalation
trials because it included prophylactic nodal RT during the
initial weeks of RT. In spite of the inclusion of prophylactic
nodal RT and concurrent chemotherapy, they were able to
boost gross disease to 90 Gy and concluded that this was safe
based on acute toxicity. However, significant chronic toxicity
did occur in three of the six patients that received 90 Gy,
which included one grade 2 esophageal stricture, one grade 3
pneumonitis, and one grade 5 hemoptysis. The median sur-
vival was quite favorable at 24 months.
Recent three-dimensional RT dose-escalation studies
targeted gross disease alone and included concurrent chemo-
therapy. Two separate phase I trials, one performed by the
RTOG (L-0117) and the other performed by NCCTG
(N0028), determined that 74 Gy in 37 daily fractions was the
MTD when administered with concurrent weekly carboplatin
and paclitaxel.29,30 Figures 1 and 2 show the dosimetry of a
patient treated with 74 Gy in 37 fractions on NCCTG trial
N0028.
Intensity-Modulated RT
IMRT uses multiple beamlets of varying intensity
within each radiation field. Planning is generally performed
with inverse planning systems and delivered with dynamic
multileaf collimators that vary the field shape actively during
RT. The multileaf collimators are computer-guided motor-
ized metal blades that extend into the radiation field and act
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as blocks. They move constantly during the IMRT to modu-
late the intensity of the beam. Inverse planning is performed
with sophisticated computer algorithms that allow the user to
prescribe specific radiation dose parameters for individual
structures. Then, the computer creates the beams to accom-
plish these goals. This is in contrast to standard forward RT
planning, which is accomplished by placing a number of
beams into the planning system and allowing the computer to
calculate the outcome in terms of dose distribution.
M. D. Anderson Cancer Center investigators performed
dosimetric studies comparing three-dimensional plans to
IMRT plans. The IMRT plans were associated with better
tumor coverage and sparing of normal tissues. They pre-
scribed 63 Gy to 95% of the planning target volume. The
planning target volume includes both gross and microscopic
disease but also accounts for movement and uncertainty.
IMRT was associated with a median reduction in the volume
of lung receiving greater than or equal to 20 Gy (V20) of 10%
with IMRT compared with three-dimensional treatment plan-
ning31,32 (Figures 3 and 4).
Holloway et al. performed a phase I trial of neoadjuvant
chemotherapy (carboplatin plus either paclitaxel or vinorel-
bine) followed by IMRT, 84 Gy in 35 daily fractions (2.4
Gy/fraction).33 One of the first five patients developed grade
5 toxicity and the trial was closed. It appears that this was too
high a starting dose for a phase I trial. More conservative
IMRT dose escalation studies are needed to define whether
this technology can deliver higher than standard doses of RT
safely.
FIGURE 1. Dosimetry from a plan for a patient treated on
NCCTG trial N0028. Tumor and adenopathy are encom-
passed within 74 Gy isodose (yellow). The five beams were
composed of 6-MV x-rays directed in the direction of the
five arrows. The isodose lines shown include the following:
76 Gy (blue), 74 Gy (yellow), 60 Gy (red), 46 Gy (beige), and
20 Gy (green).
FIGURE 2. Three-dimensional reconstruction of a plan for
the patient treated on NCCTG trial N0028 shown in Figure
1. The tumor and adenopathy (pink) are encompassed in the
74 Gy isodose cloud (blue). The other structures include the
spinal cord (blue), the esophagus (green), the heart (orange),
the left lung (gray), and the right lung (yellow).
FIGURE 3. Conventional RT plan (top) using anteroposteri-
or-posteroanterior, and opposed oblique fields followed by
an IMRT treatment plan (bottom) using a nine-field ap-
proach. Both plans deliver 60 Gy (purple isodose line) to the
tumor (red), but the volume of lung receiving 20 Gy or
greater (V20  volume encompassed by the light blue isod-
ose lines) is dramatically smaller in the IMRT plan.
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Tomotherapy
Helical tomotherapy includes IMRT delivered as the
linear accelerator rotates around the patient in a continuous
helix. This is performed with a linear accelerator mounted in
a manner analogous to a computed tomographic (CT) scan-
ner. Scrimger et al. evaluated the potential of helical tomo-
therapy compared with conventional three-dimensional field
arrangements.34 They compared plans generated for five pa-
tients with unresectable NSCLC delivering 60 Gy to the
tumor volume. The lung V20 was reduced in all cases using
tomotherapy (range, 17–37% reduction; mean reduction,
22%). The authors concluded that tomotherapy decreased the
doses administered to the normal tissues and could allow the
safe delivery of a greater dose to the tumor volume. One
additional advantage of this unit is the ability to image the
patient during therapy and evaluate the location of the tumor
to prevent geographic misses. The term “image-guided RT”
is used to describe this ability. Clinical studies are needed to
further evaluate the potential of helical tomotherapy (Figures
5 and 6).
Stereotactic RT
Stereotactic RT has been used to treat early-stage
NSCLC with favorable preliminary results compared with
historical data using conventional RT. Rowell and Williams35
performed a detailed analysis of the historical results obtained
with conventional RT for stage I to II NSCLC in patients unfit
for or declining resection. The survival at 3 years ranged from
17% to 55% and at 5 years from 0% to 42%. Local failure
occurred in 6% to 70% of patients.
In contrast to conventional RT, stereotactic techniques
include fixation, ultraprecise treatment planning, RT directed
to known disease alone, and high doses per fraction. Stereo-
tactic RT has been most commonly used for tumors within
the head.
Timmerman et al. reported a phase I trial that included
37 patients with clinical T1-2, N0, M0 NSCLCs (7cm in
diameter).36 A stereotactic body frame was used to immobi-
lize the patients that included an abdominal compression
device to limit motion of the diaphragm. Seven noncoplanar,
nonopposed beams were used to administer three doses—
each of 8, 10, 12, 14, 16, or 20 Gy—2 to 8 days apart. The
study was stopped at 20 Gy for three doses without deter-
mining an MTD, as only one patient suffered grade 3 pneu-
monitis. With a median follow-up of 15 months, six of the 46
(13%) have had local failures and the 15-month projected
survival was 64%. No patient that received doses of greater
than or equal to 18 Gy per fraction developed a local failure.
FIGURE 4. Other views of the IMRT plan from the second
patient in Figure 3. The malignancy is represented in red
and purple. The following isodoses are shown: 60 Gy (blue),
45 Gy (pink), and 20 Gy (light blue). This technique allows
sparing of the normal tissues to a greater degree than stan-
dard field setup techniques such as the use of anteroposteri-
or-posteroanterior and opposed oblique fields.
FIGURE 5. Tomotherapy unit. Helical tomotherapy includes
IMRT delivered as the linear accelerator rotates around the
patient in a continuous helix. This is performed with a linear
accelerator mounted in a manner analogous to a CT scan-
ner. (Provided by and reproduced with permission of Tomo-
Therapy, Inc., Madison, WI.)
FIGURE 6. Dose-distribution from a plan treating using to-
motherapy that shows a tight distribution of dose around
the lung tumor. A dose-volume histogram is included at the
bottom right. Doses are reported in gray. (Provided by and
reproduced with permission of TomoTherapy, Inc., Madison,
WI.)
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On the basis of this experience, the RTOG has initiated a
phase II trial (RTOG L-0236) for select patients with early-
stage medically inoperable NSCLC.
Uematsu et al. reported a trial of stereotactic RT in 50
patients with T1-2, N0, M0 NSCLC.37 They developed a
fusion of CT and linear accelerator termed a FOCAL unit.
The FOCAL unit is frameless and included a LINAC, CT
scanner, simulator, and couch. Patients generally received 50
to 60 Gy in 5 to 10 fractions over 1 to 2 weeks. Eighteen
patients also received conventional radiotherapy of 40 to 60
Gy in 20 to 33 fractions before stereotactic RT. With a
median follow-up of 36 months, local failure occurred in
three of 50 patients (6%) and nodal failure occurred in two of
50 patients (4%). The 3-year survival rate was 66%. No
definite adverse effects related to stereotactic RT were noted,
except for two patients with bone fractures and six with
pleural pain.
Onishi et al. reported on 241 patients with stage I
NSCLC treated at 13 institutions with tumors ranging from 7
to 58 mm (median, 28 mm) in diameter.38 RT included
noncoplanar dynamic arcs or multiple static ports delivering
18 to 75 Gy to the tumor in one to 22 fractions. With
follow-up of 4 to 72 months (median, 18 months), pulmonary
toxicity greater than grade 2 occurred in 2.1% and local
failure occurred in 10.4%. A higher local failure rate was
observed (20.0% versus 6.5%, p  0.04) when the biologi-
cally effective dose was less than 100 Gy versus greater than
100 Gy. Regional lymph nodes and distant metastases oc-
curred in 5.8% and 12.4%, respectively. The 3-year survival
rate was 56.0%. On the basis of these results, they plan a
phase II trial of stereotactic RT using 48 Gy in four fractions
(biologically effective dose  105.6 Gy) for patients with
stage I NSCLC.
Whyte et al. reported a phase I trial of stereotactic RT
for lung tumors (primary or metastatic) smaller than 5 cm in
diameter using the CyberKnife system (Accuray, Sunnyvale,
CA).39 The CyberKnife is a frameless system that includes a
6-MV linear accelerator mounted on a computer-controlled
robotic arm. It also uses IGRT technology with orthogonally
mounted x-ray devices to observe and correct for movements
of the bones and/or fiducial markers. Twenty-three patients
received 15 Gy in one fraction using approximately 100 beam
paths and respiratory tracking (Figures 7 and 8). There was a
greater toxicity from the placement of fiducial markers (caus-
ing three pneumothoraces) than the RT (one pulmonary
toxicity) (grade  3). With a median follow-up of 7 months,
there were two local failures and four deaths. They plan
further dose escalation to 20 Gy and then 25 Gy.
Hadron Therapy: Protons and Other Heavy
Particles
A hadron is a subatomic particle composed of quarks
that is influenced by the strong nuclear force such as a proton,
neutron, or heavy ion. Potential radiobiological advantages of
hadron RT compared with convention RT (x-rays and elec-
trons) include higher relative biological effectiveness, higher
linear energy transfer, lower oxygen enhancement ratio, and
excellent dose distribution. Each particle has its own radio-
biological characteristics. The major disadvantages of hadron
therapy are the extremely high cost and complexity. Most of
these beams exhibit a Bragg peak, except the neutron. This is
a peak in the deposited dose that occurs in tissue at a depth
very near the end of the particle’s range. It is at this spot
where the majority of the energy is deposited within tissue.
The Bragg peak occurs at a specific depth based on the
particle and the energy imparted on the particle by the
acceleration system (Figure 9). The Bragg peak is generally
so narrow that it is too small to cover most tumors. Thus, the
FIGURE 7. The CyberKnife. A linear accelerator is mounted
on a computer-controlled robotic arm. Orthogonal x-ray
cameras monitor movements that can be corrected for by
the CyberKnife. (Provided by and reproduced with permis-
sion of Accuray, Inc.).
FIGURE 8. The CyberKnife used approximately 100 beams
(blue) to treat this lung tumor. Isodose plots reveal a tight
distribution of dose around the tumor. (Provided by and re-
produced with permission of Accuray, Inc., and Dr. Lee Mc-
Neely, M.D.)
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Bragg peak must be spread out over an entire tumor’s extent
within the body. This is achieved with devices that alter the
energy of the particles and create a beam of particles with
varying energy and many Bragg peaks that, when added
together, create a wider region of maximal dose encompass-
ing the tumor (Figure 10). The process of spreading out the
Bragg peak to make it clinically useful results in an increase
in the entrance dose. One major advantage of these beams is
the lack of an exit dose. Once the particle has been stopped in
tissue, there is no further dose deposited beyond that point. In
addition to a Bragg peak, carbon ions have an increased
radiobiological effectiveness and thus a greater degree of cell
kill for a given dose than either protons or conventional x-ray
(photon) beams (Figure 11).
Bush et al. reported the Loma Linda experience treating
unresectable stage I NSCLC patients treated with proton RT.
The target included the gross tumor volume as seen on CT
scan, with additional margin to allow for respiratory motion.
Multibeam plans delivered 51 GyE in 10 fractions over 2
weeks to the first 22 patients; the subsequent 46 patients
received 60 GyE in 10 fractions over 2 weeks. Sixty-eight
patients were analyzed with a median follow-up of 30
months. There were no cases of symptomatic radiation pneu-
monitis or late esophageal or cardiac toxicity. The 3-year
local control and disease-specific survival rates were 74% and
72%, respectively. There was significantly better local tumor
control in T1 versus T2 tumors (87% versus 49%), with a
trend toward improved survival.40
Miyamoto et al. performed two phase I/II trials with
carbon ion therapy. All patients had stage I NSCLC and were
treated at the Heavy Ion Medical Accelerator in Chiba.41 The
primary tumor was irradiated without prophylactic nodal RT.
In the first study (9303), patients received 59.4 to 95.4 GyE
in 18 fractions over 6 weeks. In the second study (9701),
patients received 68.4 to 79.2 GyE in nine fractions over 3
weeks. Grade 3 lung toxicity occurred in 3.7% (3/81) and
grades 2 to 3 lung toxicity occurred in 9.8% (8 of 81). Grade
2 toxicity occurred in three of five patients at the 95.6-GyE
dose level in the first protocol and two of three patients at the
79.2-GyE dose level in the second protocol. These doses were
considered the MTD for these particular dose-fractionation
patterns. Local recurrence occurred in 19 of the 82 primary
lesions (23%). The 5-year survival rate of all 81 patients was
60%. The 5-year survival was 64.4% for stage IA and 22%
for stage IB. Local control was influenced by dose (p 0.03).
In the dose–response analysis of 9303, it was estimated that
4-year local control rates were 40% with 59.4 GyE, 55% with
64.8 GyE, 70% with 72 to 79.2 GyE, and 80% with greater
than or equal to 86.4 GyE. The authors felt that the local
FIGURE 9. Depth–dose curves for three beams including a
megavoltage (MV) x-ray beam (dashed), a single energy pro-
ton beam (blue), and a multiple energy proton beam (red).
The MV x-ray beam peaks in dose deposition a few centime-
ters beyond the entrance point. The single energy proton
beam enters the body, depositing a small fraction of the
dose until it reaches the depth of the Bragg peak, and most
of its dose is deposited in this very narrow range at a specific
depth defined by the beam energy. Most tumors will not fit
in this narrow Bragg peak. Therefore, the Bragg peak is
spread out by using multiple energy protons, which make
the beam clinically useful. This also results in an increased
entrance dose (the dose near the patient’s surface) of the
beam compared with a single energy beam. The protons
stop at the end of their range, yielding little, if any, exit
dose. (Modified and used with permission of the Indiana
University Cyclotron Facility. Available at: http://www.iucf.in-
diana.edu/Experiments/RadioBiology/papers/dose5.html.)
FIGURE 10. The same as in Figure 8. The same three
beams’ depth–dose curves are found: the x-ray beam is
dashed, the single energy proton beam is denoted as non-
modulated, and the multiple energy proton beam is de-
noted as modulated. A tumor is shown at a depth between
40 and 75 mm from the surface of the patient. The single
energy proton beam does not provide adequate tumor cov-
erage with dose because of the narrow Bragg peak. The
modulated proton beam provides better tumor coverage in
the spread out Bragg peak. The region of potential dosimet-
ric advantage between the modulated proton beam and the
x-ray beam is shown with crosshatching. (From the National
Physical Laboratory, Teddington, Middlesex, United King-
dom. Available at: http://www.npl.co.uk/publications/news/
ionrad/ionisingrad_issue13_pic01.jpg. (C) Crown Copyright
2005. Reproduced with the permission of the Controller of
HMSO and the Queen’s Printer for Scotland.)
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control (77%) achieved with carbon ion RT was equivalent to
surgical resection.
CONCLUSIONS
During the past three decades, there has been progress
in the understanding of lung cancer, resulting in improve-
ments in treatment and patient survival.3 Radiation has a key
role in treating lung cancer. Innovations include altered
fractionation patterns, three-dimensional treatment planning,
IMRT, tomotherapy, stereotactic RT, hadron therapy, and
better systemic therapy. Recent studies suggest that newer
techniques may enhance the outcome of patients with lung
cancer by allowing the safe delivery of greater doses of RT.
With regard to a simpler treatment innovation, TIDRT ap-
pears better than QDRT.
Chemotherapy has been shown to increase the survival
of most patients with lung cancer. Systemic therapy is evolv-
ing to targeted therapy specific to molecular abnormalities
present in an individual tumor. It is hoped that targeted
therapy will yield better survival and less toxicity. More
research is needed combining targeted agents with RT. We
also need a greater understanding of the molecular events that
take place in irradiated cells so that targeted agents can be
designed specifically to improve the therapeutic index of RT.
Quite soon, we will be able to image a patient on the
same device used to deliver ultraprecise high-dose RT. This
device will need to correct for patient movement. All known
disease including both local disease and metastases will be
targeted and irradiated to huge doses, sparing normal tissues.
These future RT systems may provide disease control more
safely and effectively than resection. Innovations such as
those described will only be possible with continued research.
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